Log In Get Started
Insider Trading April 20, 2026 04:07 PM

Tivic Health Director Purchases $10,400 of Company Stock as Strategic Shift Continues

Director Sheryle Bolton buys 10,000 shares amid recent volatility while Tivic advances Entolimod research and a biopharma pivot

By Leila Farooq TIVC
Tivic Health Director Purchases $10,400 of Company Stock as Strategic Shift Continues
TIVC

Sheryle Bolton, a member of Tivic Health Systems' board, purchased 10,000 shares of the company's common stock on April 15, 2026, spending $10,400 at $1.04 per share. The trade comes as the stock has rallied 38% in the past week but remains down 56% over six months. Tivic is repositioning itself from consumer devices toward a biopharmaceutical focus centered on a TLR5 immunotherapy platform and Entolimod, with several regulatory and research activities underway.

Key Points

  • Director Sheryle Bolton purchased 10,000 shares of Tivic Health at $1.04 per share on April 15, 2026, totaling $10,400.
  • TIVC stock rose 38% over the past week but is down 56% over the last six months; InvestingPro lists the stock as trading at $1.13 and appearing undervalued.
  • Tivic is shifting from consumer devices to biopharmaceuticals, focusing on a TLR5 immunotherapy platform and advancing Entolimod through regulatory inquiries and NIAID-sponsored preclinical studies.

Insider purchase

Sheryle Bolton, a director at Tivic Health Systems, Inc. (NASDAQ:TIVC), executed a direct purchase of 10,000 shares of the company’s common stock on April 15, 2026. The acquisition was priced at $1.04 per share, resulting in a $10,400 outlay. Following the transaction, Bolton directly holds 10,000 shares of Tivic Health Systems, Inc. common stock.

Market context

The timing of the purchase coincides with notable short-term price movement: the stock has increased roughly 38% over the last week while still trading about 56% below its level six months ago. InvestingPro analysis referenced by market observers indicates that TIVC appears undervalued at current levels, with the stock noted as trading at $1.13.

InvestingPro subscribers are reported to have access to 13 additional ProTips for TIVC, which include commentary and data points on the company’s cash position and patterns of price volatility.

Company strategy and research activity

In its Q4 2025 earnings call, Tivic Health Systems disclosed a strategic reorientation of its business model, moving away from consumer devices and toward biopharmaceutical operations. The company said it is focusing on developing a TLR5 immunotherapy platform, with Entolimod identified as a key asset in that effort.

Several specific regulatory and research interactions were also announced. Tivic reported receiving a Request for Information from the Ukrainian Ministry of Health to assess Entolimod for potential inclusion in Ukraine’s national strategic reserves as a countermeasure against Acute Radiation Syndrome. The Ukrainian Ministry additionally requested a pre-submission meeting regarding Entolimod.

Separately, Tivic has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to sponsor preclinical studies evaluating Entolimod for gastrointestinal acute radiation syndrome. Those studies, funded by NIAID, are slated to be conducted at the Armed Forces Radiobiology Research Institute and aim to evaluate Entolimod’s capacity to protect gastrointestinal tissue and reduce radiation-induced mucosal necrosis following lethal-dose radiation exposure.

Takeaway

The insider purchase by a company director occurs alongside an announced strategic pivot to biopharmaceuticals and a series of regulatory and preclinical activities focused on Entolimod. The transaction and the research developments are factual milestones in Tivic’s ongoing repositioning efforts.

Risks

  • Price volatility - The stock has shown marked short-term movement (up 38% in the past week) and substantial decline over six months (down 56%), indicating market uncertainty in the equity - this impacts equity investors and market participants.
  • Regulatory and development uncertainty - Tivic’s pivot to biopharmaceutical operations and ongoing preclinical and regulatory interactions for Entolimod carry execution and regulatory timing risks - this affects the biotech and pharmaceutical sectors.
  • Concentration risk for shareholders - A director’s direct ownership of 10,000 shares represents a specific insider position but does not by itself indicate broader institutional support; investor confidence may be sensitive to subsequent corporate and clinical milestones.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026